| Document |
Document Title |
|
WO/2018/106807A1 |
The invention provides compositions and methods for treating MPS I.
|
|
WO/2018/104762A1 |
The invention relates to the use of cationic nanoparticles for enhancing the infectious capacity of non-enveloped virus.
|
|
WO/2018/106847A1 |
The inventive technology relates to novel systems, methods, and strategies for the control of plant pathogens and herbivores. The inventive technology may specifically include novel compositions, systems, and methods configured to delive...
|
|
WO/2018/107103A1 |
The present invention generally relates to plants comprising a CRISPR system or parts of a CRISPR system, compositions, containers, polynucleotide, vectors, delivery systems, parts of plants, methods for production, CRISPR systems, and c...
|
|
WO/2018/103037A1 |
An SNP marker combination for rice genotyping and a design method, and a chip designed for the SNP markers and an application thereof.
|
|
WO/2018/104267A1 |
The application generally relates to chloroplast targeting of nuclear-encoded proteins of interest in microalgae. Provided herein are expression cassettes comprising a nucleotide sequence encoding a chloroplast targeting peptide operably...
|
|
WO/2018/104919A1 |
The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., ra...
|
|
WO/2018/106615A2 |
The present disclosure generally relates to nucleic acid molecules for use in regulating gene expression. Disclosed herein include nucleic acid molecules containing one or more structural elements of the viral capsid enhancer operably li...
|
|
WO/2018/106268A1 |
The present invention includes methods and compositions for elimination of polyoma viruses, such as John Cunningham Virus (JVC), from host cells, and the treatment of polyoma-virus related diseases, such as progressive multifocal leukoen...
|
|
WO/2018/104544A1 |
The present invention relates to a combination of cationic nanoparticles and viruses and uses thereof. The invention particularly relates to the use of nanoparticles for enhancing the infectious capacity of a live virus, preferably a non...
|
|
WO/2018/106782A1 |
A method of generating a cell that enhances functional myelin production is provided, the method including genetically modifying the cell such that: (i) an endogenous PLP1 gene is modified to decrease its ability to inhibit myelin produc...
|
|
WO/2018/104911A1 |
The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said...
|
|
WO/2018/106566A1 |
Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
|
|
WO/2018/105420A1 |
A method for constructing a transformant, said method comprising using an alga belonging to the genus Nannochloropsis, in which the function of protein (A) or (B) is suppressed, inhibited or deleted, as a host. (A) A protein which compri...
|
|
WO/2018/103631A1 |
The present invention provides a fusion protein of Slit2D2 (C386S) and HSA, and use thereof in the treatment and/or prevention of fibrotic diseases. In the fusion protein, cysteine at position 386 in Slit2D2 domain mutates into serine, w...
|
|
WO/2018/107003A1 |
CRISPR/Cas9-mediated genome editing holds clinical potential for treating genetic diseases, such as Duchenne muscular dystrophy (DMD), which is caused by mutations in the dystrophin gene. In vivo AAV-mediated delivery of gene-editing com...
|
|
WO/2018/103502A1 |
Provided is a CAR-T transgenic vector for alleviating, via IL-6R knockout, cytokine release syndrome (CRS). The vector comprises: an ampicillin resistance gene sequence; a prokaryotic replicon pUC Ori sequence; a viral replicon SV40 Ori ...
|
|
WO/2018/106956A2 |
The present disclosure relates to compositions and methods for treatment of degenerative conditions of large weight-bearing joints, such as osteoarthritis, by intra-articular delivery of a codon-modified IL-1Ra encoding gene.
|
|
WO/2018/106992A1 |
RNA nanoparticles functionalized with a HER2-targeting RNA aptamer and at least one MED1 siRNA for targeted delivery of MED1 siRNA to human cancer cells via human epidermal growth factor receptor 2 (HER2) receptors, pharmaceutical compos...
|
|
WO/2018/106849A1 |
Peripheral blood mononuclear cells (PBMCs) can be used in place of DCs when pulsing with antigens, or antigen and adjuvant combination, and then administered to a subject as a vaccine to induce a protective immune response. The PBMC-base...
|
|
WO/2018/106753A1 |
Described herein are methods and compositions relating to the treatment of a tumor (e.g., schwannoma) by increasing expression of Apoptosis-associated Speck-like protein containing a CARD (ASC) and/or gasdermin D. In some embodiments, th...
|
|
WO/2018/103067A1 |
Disclosed is a marker for real-time observing effects of a compound or a drug on cells. The marker comprises: 1) an amino acid sequence shown in SEQ NO: 1 and/or SEQ NO: 2; or 2) an amino acid sequence having a function for real-time obs...
|
|
WO/2018/103734A1 |
Disclosed are a chimeric antigen receptor (CAR) and the use thereof and a preparation method therefor, a T-cell containing the chimeric antigen receptor, a nucleic acid sequence encoding the chimeric antigen receptor, a vector comprising...
|
|
WO/2018/106648A1 |
Lipid-based probes and systems therewith to capture and isolate extracellular vesicles from a sample are disclosed. The system can include a labelling probe-capture probe combination or an immobilized labelling probe on a surface of a su...
|
|
WO/2018/107028A1 |
This disclosure relates to modified single and dual guide RNAs having improved in vitro and in vivo activity in gene editing methods.
|
|
WO/2018/107129A1 |
The embodiments disclosed herein utilized RNA targeting effectors to provide a robust CRISPR-based diagnostic with attomolar sensitivity. Embodiments disclosed herein can detect both DNA and RNA with comparable levels of sensitivity and ...
|
|
WO/2018/106724A1 |
In certain embodiments an optimized derivative of the CCLc-βAS3-FB lentiviral vector termed (CCLc-mGata/ANK-CoreLCR-βAS3-FB), is provided which is capable of driving lineage-restricted expression of a beta-globin gene (e.g., an anti-si...
|
|
WO/2018/103501A1 |
Provided are a human PD-1 knockdown siRNA, a recombinant expression CAR-T vector, a preparation method thereof, and an application of the same. A PD-1 knockdown siRNA expression cassette and an siRNA expression product thereof can be app...
|
|
WO/2018/105404A1 |
A reaction processing device 100 comprises: a container placement unit 74 for placing a reaction processing container 10 comprising a channel formed on a substrate; a high-temperature heater 104 and an intermediate-temperature heater 106...
|
|
WO/2018/106721A1 |
This disclosure provides methods for generating functionalized nanoswitches, as well as the functionalized nanoswitches themselves, and methods of use thereof.
|
|
WO/2018/104385A1 |
Method for determining an optimized nucleotide sequence encoding a predetermined amino acid sequence, wherein the nucleotide sequence is optimized for expression in a host cell, and wherein the method comprises the steps of: (a) generati...
|
|
WO/2018/106892A1 |
The invention features compositions and methods for identifying orthogonal transcriptional switches derived from Tet repressor homologs for Saccharomyces cerevishiae regulated by 2,4-diacetylphloroglucinol (DAPG) and other ligands.
|
|
WO/2018/106792A1 |
Provided herein are recombinant host cells having a heterologous polynucleotide encoding a hexose transporter and a heterologous polynucleotide encoding a xylose isomerase, wherein the cells are capable of fermenting xylose in the presen...
|
|
WO/2018/105302A1 |
This device is provided with: a casing having a sample dropping section which receives a liquid sample that contains a nucleic acid and that is dropped on the upper surface from a nozzle; a reaction tube which protrudes outward from an e...
|
|
WO/2018/103686A1 |
Provided is a chloroplast genome editing method. In particular, provided are a nucleic acid construct, a vector, or a vector combination for plant genome site-specific editing based on a CRISPR technology, and a plant genome site-specifi...
|
|
WO/2018/104407A1 |
The present invention relates to modified T cell receptor (TCR) α or β chains, or heterodimers comprising the same, wherein in the variable domain of said modified α or β chain, an amino acid at position 44 according to the IMGT numb...
|
|
WO/2018/107061A1 |
Provided herein are lipid-based nanoparticles (e.g., exosomes) having (a) a core comprising a cationic polymer and a therapeutic agent (e.g., a therapeutic protein, an antibody, an inhibitory RNA, and/or a small molecule drug) and (b) a ...
|
|
WO/2018/104893A1 |
The invention relates to novel α4β7antigen binding proteins. In particular, the invention relates to modified antigen binding proteins that are novel variants of anti-a4(37 antibodies, such as vedolizumab, which show increased binding ...
|
|
WO/2018/106982A1 |
The present invention provides compositions and methods for enhancing beta cell maturation, health and function. The invention may be used for increasing insulin secretion in a cell, promoting the formation of cell clusters, or reducing ...
|
|
WO/2018/104596A1 |
The invention relates to a method for increasing the content of C18:3 fatty acid or alpha-linolenic acid in flaxseed, and to the resulting plants, which method involves increasing the expression of the Δ15 desaturase responsible for the...
|
|
WO/2018/105748A1 |
The present invention addresses the problem of providing a method which enables the introduction of a foreign substance into a single cell with high efficiency and easily and is less likely to be influenced by the damage of the cell. A c...
|
|
WO/2018/104724A1 |
The invention relates to methods and agents for increasing the frequency of crossover events during meiosis in plant cells. For this purpose, the method comprises the step of increasing the activity and/or levels of an HEI10 protein in t...
|
|
WO/2018/106727A1 |
The present disclosure provides engineered Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic acid-targeting nucleic acids, nucleoprotein complexes comprising these nucleic acids, and compositions thereof. Nucleic acid sequen...
|
|
WO/2018/106732A1 |
Provided are methods for genetically engineering cells, including cells for use in connection with genetic engineering. In some embodiments, the provided methods including transduction of cells by incubation with a retroviral vector part...
|
|
WO/2018/106693A1 |
Engineered nucleic acids encoding genome editing system components are provided, as are engineered RNA-guided nucleases that include inserts encoded in part by cellular genomic or other sequences recognized by guide RNAs.
|
|
WO/2018/104554A1 |
Methods of cancer treatment comprise administration of a natural killer (NK) cell or cell line in combination with an IL-6 antagonist, such as an antibody to IL-6 or its receptor, especially for treatment of cancer expressing IL-6 recept...
|
|
WO/2018/105560A1 |
The purpose of the present invention is to provide a novel technique for controlling the blood-brain barrier. An antibody of which the epitope is a region located in an extracellular domain of Claudin 5 protein.
|
|
WO/2018/103503A1 |
Provided is a PD-L1 knockout CAR-T transgenic vector for suppressing immune escape, comprising: an ampicillin resistant (AmpR) sequence as indicated by SEQ ID NO. 1; a prokaryotic replicon pUC Ori sequence as indicated by SEQ ID NO. 2; a...
|
|
WO/2018/106470A1 |
The present invention is drawn to compositions and methods for improving transformation frequency. The compositions, synthetic selectable marker genes, are used in transformation methods and result in increased transformation frequency.
|
|
WO/2018/106821A1 |
The invention provides compositions and methods for treating Hunter Syndrome.
|
